Solution provided
Supplier identity
General description

DIAGAM operates in the Biotechnology sector and is particularly active in the field of In Vitro Diagnosis.
DIAGAM develops and produces liquid reagents for medical laboratories.

Type of Supplier
Biotechnology R&D Company - Diagnostics / Devices and Diagnostics Services
Sector of activity
  • Animal Health Products
  • Diagnostics / Devices and Services
  • Gastroenterology
  • In vitro Diagnostics
  • Nanobiotechnologies
Region of Wallonia, BE
Regional access broker
  • Claire Bajou, Interface Enterprises-University of Liège
  • Annick Pierrard, Interface Enterprises-University of Liège
Activity description
Know-how, expertise available

Our R&D department aims its work to developing classical immunology technologies as well as new and innovative technologies based on nanotechnologies.
DIAGAM is the world's leading provider of liquid laboratory reagents containing gold particles. We are therefore currently taking part in a project to develop new nanotechnologies based on the use of colloidal particles in the field of medical diagnosis. This is a project supported by the Walloon Region.

-Reagents manufacturing for specific proteins:
Development of reagents for the titration of specific proteins either with classical immunoturbidimetric methods, either with innovating nanoparticles technologies, at this day, on our direct market we are considered as a major specialist of specific proteins.

-Technical engineering:
Development of applicative aspect on high speed analyzers from Ortho Clinical Diagnostics, Roche, Abbott, Siemens, Olympus-Beckman. This involves the provision of bottles code barred 100% compatible with the analytical system.
(*all brands quoted are registrated trademarks)

-Gold nanoparticles:
The company is engaged in high technology Research & Development activities.
The current projects include new technologies based on gold nanoparticles as labels under stable colloidal solution form applied in completely homogeneous immunoassays for automated
biochemistry analysers.
These activities have succeeded in bringing the following original products to the market :
Rheumatoid factor and Ferritin reagents based on colloidal gold solution for use in immunocolorimetry assay formats. Advantages over existing technologies: perfectly adaptable on opened biochemistry analysers, ease of reagent handling, low costs, improved specificity.

Possibilities of partnership

In the past we worked mainly through distributors, including in Belgium and France, last 3-5 years we developed direct commercialization of our products in the aim to obtain more relevant information about the use of our reagents and about the exactly needs of the market, moreover we developed, with our past French distributor, the bare coded vials for ROCHE systems (HITACHI and MODULAR)

With the development of the FIBROTEST (including the titration of alpha-2-macroglobulin protein) in France we have had the opportunity to develop a collaboration with the 5 major actors of the diagnostic market. This collaboration allows us to learn more and more about the analytical systems and to develop methodologies for most of big analyzers.

Moreover our direct strategy in Belgium, France and Portugal allowed us to proposed completely fitted and bare coded reagents for most of those biggest systems

We concluded some agreements with the “big five competitors”, for instance with Ortho Diagnostics in France; we are now their supplier for 10 specific proteins (including CRP) on VITROS systems, in this aim we are working at this day on complete technical files in conformity with norm 15189 for the VITROS.

We started this new big system strategy in Europe at the end of 2010, we are know investigating other European markets as Italy, Germany, Denmark, United Kingdom. Our goal is to develop a spotting system of commercialization by identifying previously the “DIAGAM Profile Customer” with an appropriate market study.

We also use our references laboratories like Pasteur Cerba, Biomnis or CHU of Pitié Salepétrière in France like door openers for our new prospects.

Using our positive results on the markets, we can better select our distribution networks.

Terms of availability for SMEs

Referring to the small size of our Company, strategic development could follow the next procedure:

Direct investigation in small & big labs in Europe, including commercialization, followed by an appropriate selection of local distributors technically accompanied by our structure.

Generate interest among major players in the in vitro diagnostic, with complementary products from our development or from our new technologies.

Initiate join venture collaboration with reliable partners with converging interests and complementary skills in order to enter new markets with a strategy similar to that applied in Europe.

Quality labels and accreditations

2003 CE registration for all products

2005 certification for ISO 9001-2000

2005 certification for ISO 13485

2009 certification for ISO 9001-2008

2008 member of the European BIO & Diagnostic Cluster BIOWIN and WallDX

2009 foundation of nanoQ, LTD sister Company specialized in the synthesis and coating of metallic nanoparticles

2010 implementation of the standard 15189 in the establishment of technical records

All reagents are liquid, stable and ready for use

All calibrators are immediately calibrated against international reference material as: IFCC, CRM 470, WHO, CDC….

Barcode available for specific analysers

Validated applications for all opened Biochemistry Analysers

Training and Staff possibilities
Training and Staff exchange terms and conditions

DIAGAM has the habit to take student placement for the R&D department.
We are always looking for the best and motivated students to work with us for some projects. This will depend on the needs of our company.

Contact information
Business Developer
Phone number
+33 (0) 6 24 02 06 72
rue du Parc Industriel
7822  Ghislenghien